ISSN: 1885-5857 Impact factor 2023 7.2
Vol. 68. Num. 1.
Pages 10-16 (January 2015)

Editorial
Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

Comentarios a la guía de práctica clínica de la ESC 2014 sobre el diagnóstico y tratamiento de la embolia pulmonar aguda

SEC Working Group for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism Expert Reviewers for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism SEC Clinical Practice Guidelines Committee
Rev Esp Cardiol. 2015;68:6410.1016/j.rec.2014.12.002
Stavros Konstantinides, Adam Torbicki, Giancarlo Agnelli, Nicolas Danchin, David Fitzmaurice, Nazzareno Galiè, J. Simon R. Gibbs, Menno Huisman, Marc Humbert†, Nils Kucher, Irene Lang, Mareike Lankeit, John Lekakis, Christoph Maack, Eckhard Mayer, Nicolas Meneveau, Arnaud Perrier, Piotr Pruszczyk, Lars H. Rasmussen, Thomas H. Schindler, Pavel Svitil, Anton Vonk Noordegraaf, Jose Luis Zamorano, Maurizio Zompatori

Options

Este artículo solo puede leerse en pdf
References
[1]
M. Anguita, A. Fernández-Ortiz, F. Worner, A. Alonso, A. Cequier, J. Comín, et al.
La Sociedad Española de Cardiología y las guías de práctica clínica de la ESC: hacia una nueva orientación.
Rev Esp Cardiol., (2011), 64 pp. 795-796
[2]
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014 Aug 29 [in press]. pii: ehu283.
[3]
M. Righini, J. Van Es, P.L. Den Exter, P.M. Roy, F. Verschuren, A. Ghuysen, et al.
Age- adjusted d-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.
JAMA., (2014), 311 pp. 1117-1124
[4]
P.D. Stein, S.E. Fowler, L.R. Goodman, A. Gottschalk, C.A. Hales, R.D. Hull, et al.
PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism.
N Engl J Med., (2006), 354 pp. 2317-2327
[5]
S. Laporte, P. Mismetti, H. De’cousus, F. Uresandi, R. Otero, J.L. Lobo, et al.
Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.
Circulation., (2008), 117 pp. 1711-1716
[6]
S.Z. Goldhaber, L. Visani, M. De Rosa.
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
Lancet, (1999), 353 pp. 1386-1389
[7]
D. Aujesky, D.S. Obrosky, R.A. Stone, T.E. Auble, A. Perrier, J. Cornuz, et al.
Derivation and validation of a prognostic model for pulmonary embolism.
Am J Respir Crit Care Med., (2005), 172 pp. 1041-1046
[8]
D. Jiménez, D. Aujesky, L. Moores, V. Gómez, J.L. Lobo, F. Uresandi, et al.
Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
Arch Intern Med., (2010), 170 pp. 1383-1389
[9]
M. Righini, P.M. Roy, G. Meyer, F. Verschuren, D. Aujesky, G. Le Gal.
The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism.
J Thromb Haemost., (2011), 9 pp. 2115-2117
[10]
D. Aujesky, P.M. Roy, F. Verschuren, M. Righini, J. Osterwalder, M. Egloff, et al.
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
[11]
G. Meyer, E. Vicaut, DanaysT, G. Agnelli, C. Becattini, J. Beyer-Westendorf, et al.
Fibrinolysis for patients with intermediate-risk pulmonary embolism.
N Engl J Med., (2014), 370 pp. 1402-1411
[12]
S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, et al.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
N Engl J Med., (2009), 361 pp. 2342-2352
[13]
S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, et al.
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Circulation., (2014), 129 pp. 764-772
[14]
R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Büller, H. Decousus, A.S. Gallus, et al.
Oral rivaroxaban for symptomatic venous thromboembolism.
N Engl J Med., (2010), 363 pp. 2499-2510
[15]
H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, et al.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
N Engl J Med., (2012), 366 pp. 1287-1297
[16]
G. Agnelli, H.R. Büller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, et al.
Oral apixaban for the treatment of acute venous thromboembolism.
N Engl J Med., (2013), 369 pp. 799-808
[17]
H.R. Büller, H. Decousus, M.A. Grosso, M. Mercuri, S. Middeldorp, M.H. Prins, et al.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med., (2013), 369 pp. 1406-1415
[18]
H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, et al.
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
Eur Heart J., (2013), 34 pp. 2094-2106
[19]
Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas- Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 2014 Jul 6 [in press]. doi: 10.1016/j.thromres.2014.06.020.
[20]
P.M. Ridker, S.Z. Goldhaber, E. Danielson, Y. Rosenberg, C.S. Eby, S.R. Deitcher, et al.
PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
N Engl J Med., (2003), 348 pp. 1425-1434
[21]
C. Kearon, J.S. Ginsberg, M.J. Kovacs, D.R. Anderson, P. Wells, J.A. Julian, et al.
Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
N Engl J Med., (2003), 349 pp. 631-639
[22]
S. Husted, R. De Caterina, F. Andreotti, H. Arnesen, F. Bachmann, K. Huber, et al.
ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost., (2014), 111 pp. 781-782
[23]
A. Amin, Y. Jing, J. Trocio, J. Lin, M. Lingohr-Smith, J. Graham.
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
J Med Econ., (2014), 12 pp. 1-8
[24]
M.L. Louzada, M. Carrier, A. Lazo-Langner, V. Dao, M.J. Kovacs, T.O. Ramsay, et al.
Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
Circulation., (2012), 126 pp. 448-454

A full list of the names of all authors are shown in the Appendix.

Copyright © 2014. Sociedad Española de Cardiología
Are you a healthcare professional authorized to prescribe or dispense medications?